Early Stage Bladder Cancer

About Early Stage Bladder Cancer

AADi is currently investigating the intravesical (administered into the bladder) use of ABI-009 in early stage or Non-Muscle Invasive Bladder Cancer (NMIBC) in a multi-center phase 1/2 study funded by a NIH fast-track STTR grant (R42CA171552) from the National Cancer Institute.

The phase 1 study has been completed and a combination phase 2 study (ABI-009 + gemcitabine, a standard of care) is ongoing (NCT02009332).


70,000 new cases of bladder cancer each year in the US, ~15,000 deaths
70-80% present with non-muscle invasive bladder cancer (NMIBC)
50% relapse after BCG treatment
Large prevalence pool (150k pts)
Limited treatment options for intravesical treatment
Trial initiated, NIH Funded

Early Stage Bladder Cancer

March, 7 2019, Aadi Bioscience, Inc. (Aadi), For the first time in his life, Shanahan “Shanny” Dameral, 19, has a girlfriend. Soon, he’ll be graduating with a high school diploma and looking for his first job on the Kitsap Peninsula. What seems routine for many is a big deal for Dameral and other children living with treatment-resistant or intractable epilepsy. For reasons largely unknown, seizures in this subset of children persist long past their discovery in early childhood despite being treated with multiple medications and undergoing surgery to remove the affected parts of their brain. Diagnosed with epilepsy at age 5, life for Dameral has always come with seizures attached. When his seizures returned after a second brain surgery shortly after his 16th birthday, his mom Linley Allen, hoped for a medical breakthrough. “We needed to find something else since another surgery was out of the question,” Allen said. “We had heard about a drug being studied for a more severe seizure condition. I kept holding onto hope that it might be expanded to treat Shanny’s type of seizures because it was all we had at the time.”   See all and the original News article here: New Drug Trial Gives Hope for Treatment-Resistant Epilepsy